The estimated Net Worth of Lucy Lu is at least 1.03 百万$ dollars as of 10 February 2023. Lucy Lu owns over 11,976 units of Avenue Therapeutics Inc stock worth over 386,799$ and over the last 7 years he sold ATXI stock worth over 0$. In addition, he makes 639,783$ as President、 Chief Executive Officer、 Director at Avenue Therapeutics Inc.
Lucy has made over 2 trades of the Avenue Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 11,976 units of ATXI stock worth 10,060$ on 10 February 2023.
The largest trade he's ever made was buying 11,976 units of Avenue Therapeutics Inc stock on 10 February 2023 worth over 10,060$. On average, Lucy trades about 932 units every 30 days since 2017. As of 10 February 2023 he still owns at least 133,379 units of Avenue Therapeutics Inc stock.
You can see the complete history of Lucy Lu stock trades at the bottom of the page.
Dr. Lucy Lu M.D. serves as President, Chief Executive Officer, Director of the Company. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. Additionally, Dr. Lu was a member of the Board of Directors of Veru, Inc. from 2016 – 2018, and has served as a member of the Board of Directors of Iventia Healthcare Limited since 2018. From February 2007 through January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of the firm in February 2006. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science. Lu is qualified to serve on our Board due to her leadership and management experience, her understanding of biopharmaceutical companies, and her extensive knowledge of our business and industry.
As the President、 Chief Executive Officer、 Director of Avenue Therapeutics Inc, the total compensation of Lucy Lu at Avenue Therapeutics Inc is 639,783$. There are no executives at Avenue Therapeutics Inc getting paid more.
Lucy Lu is 45, he's been the President、 Chief Executive Officer、 Director of Avenue Therapeutics Inc since 2015. There are 9 older and 2 younger executives at Avenue Therapeutics Inc. The oldest executive at Avenue Therapeutics Inc is Dr. Scott A. Reines M.D., Ph.D., 74, who is the Interim Chief Medical Officer.
Lucy's mailing address filed with the SEC is 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over 3,169,091$ worth of Avenue Therapeutics Inc stock and bought 867,969 units worth 1,169,423$ . The most active insiders traders include Lindsay A Md Rosenwald、Michael S Weiss、Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of 210,758$. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth 86,380$.
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include: